Mazdutide: Innovent's GLP-1 / Glucagon Dual Agonist for the Asian Market

What mazdutide is

Mazdutide (formerly identified as IBI362) is a synthetic peptide that activates two receptors: the GLP-1 receptor and the glucagon receptor. It is developed by Innovent Biologics, a Suzhou-based Chinese pharmaceutical company, under license from Eli Lilly's original research.

The licensing arrangement is the key context. Eli Lilly developed the underlying molecule but chose to focus its own US/global commercial efforts on tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple). Mazdutide was out-licensed to Innovent for development primarily in China and other Asian markets, where Innovent has the infrastructure and commercial focus.

The Asia-first regulatory pathway

Most novel obesity drugs pursue US FDA approval as the lead indication, with global approvals following. Mazdutide has done the opposite: lead approval through China's NMPA (National Medical Products Administration), with potential Western applications later.

Key regulatory milestones:

• 2024: NMPA approved mazdutide for type 2 diabetes in China.
• 2024-2025: Phase 3 trials for chronic weight management indication in Chinese patients.
• Western development: not a near-term priority; Lilly retains rights for US development if it chooses to pursue them.

The China-first strategy makes sense for several reasons: China has the world's largest population of adults with obesity and type 2 diabetes by absolute number; the NMPA pathway can be faster than FDA for drugs developed locally; and Innovent has the commercial reach in China that Eli Lilly does not.

Phase 3 results in Chinese patients

The pivotal Chinese Phase 3 trials of mazdutide in patients with obesity and overweight without diabetes (GLORY-1 and related) showed:

• ~15% mean weight loss at 32 weeks at the highest dose (vs ~1% placebo).
• Strong HbA1c reduction in diabetic subpopulations.
• Liver fat reduction consistent with the glucagon-arm effects.
• Tolerability qualitatively similar to other GLP-1 drugs.

The 15% magnitude is competitive with semaglutide's STEP-1 result and slightly below survodutide's Phase 2 magnitude. The trial duration was shorter than typical Western Phase 3 (32 weeks vs 68-72 weeks), so the comparable-magnitude framing carries some uncertainty about long-term trajectory.

How mazdutide compares to other glucagon-arm drugs

Mazdutide sits in the same drug family as survodutide and pemvidutide — GLP-1 / glucagon dual agonists. Differences:

• Mazdutide (Innovent): Approved in China for T2D since 2024; weight management approval following. Phase 3 evidence in Asian populations.
• Survodutide (Boehringer / Zealand): Phase 3 ongoing in Western markets; expected approval 2027-2028. Larger pharmaceutical sponsor, broader indication strategy.
• Pemvidutide (Altimmune): Phase 3 ongoing with MASH-focused positioning; small biotech approach.

Mazdutide is the most clinically advanced of the three by approval status — actually approved and prescribed in China while the others are still in trials. For global comparison, survodutide is closest to Western approval; mazdutide is closest to actual prescribed use.

Differences in Asian population data

One observation worth noting: GLP-1 drugs sometimes show different efficacy and tolerability profiles in Asian populations compared with Western trial populations. Asian patients often respond well to lower absolute doses, partly because of differences in body mass and partly because of incompletely understood pharmacogenomic factors. The Chinese mazdutide trials may produce magnitude estimates that don't directly translate to Western populations — something to factor when comparing mazdutide's ~15% to survodutide's Western Phase 2 ~19%.

The honest read

Mazdutide is the most under-discussed major-pharmaceutical GLP-1 drug in Western coverage — partly because the Asia-first development pathway puts it outside the FDA conversation, partly because the licensing structure (Lilly's molecule, Innovent's development) is unusual. But it is genuinely approved and being prescribed in China for type 2 diabetes, and it represents the first member of the glucagon-arm dual-agonist family to reach actual commercial use.

For Western audiences, mazdutide is most relevant as an early signal of where the broader class is heading. Real-world data from Chinese patients on mazdutide will inform how the regulatory and clinical communities think about survodutide and pemvidutide when those reach the Western market. For Chinese patients today, mazdutide is one of the available options alongside locally-available semaglutide and other GLP-1 drugs.